Share This Page
Drug Price Trends for IMURAN
✉ Email this page to a colleague
Average Pharmacy Cost for IMURAN
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| IMURAN 50 MG TABLET | 54766-0590-10 | 8.89067 | EACH | 2025-04-04 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for IMURAN
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Unit | Dates | Price Type |
|---|---|---|---|---|---|---|---|---|
| IMURAN 50MG TABLET | Sebela Pharmaceuticals, Inc. DBA Sebela Pharmaceuticals, Inc. | 54766-0590-10 | 100 | 565.13 | 5.65130 | EACH | 2024-04-01 - 2029-03-31 | Big4 |
| IMURAN 50MG TABLET | Sebela Pharmaceuticals, Inc. DBA Sebela Pharmaceuticals, Inc. | 54766-0590-10 | 100 | 826.79 | 8.26790 | EACH | 2024-04-01 - 2029-03-31 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Unit | >Dates | >Price Type |
IMURAN (Azathioprine) Market Analysis and Price Projections
Summary: Imuran (azathioprine) is an established immunosuppressant used in organ transplantation and autoimmune diseases. Its market is characterized by generic competition and a stable, albeit mature, demand driven by chronic conditions. Price projections indicate continued modest increases due to manufacturing costs and inflation, with limited impact from new market entrants or significant therapeutic advancements in the short to medium term.
What is Imuran and its Therapeutic Applications?
Imuran, the brand name for azathioprine, is an antimetabolite that acts as a purine analogue. It interferes with DNA and RNA synthesis, thereby inhibiting the proliferation of rapidly dividing cells, particularly lymphocytes. This mechanism underlies its immunosuppressive properties, making it effective in preventing organ rejection following transplantation and in managing various autoimmune conditions.
Key therapeutic applications include:
- Organ Transplantation: Azathioprine is used to prevent rejection of kidney, heart, and liver transplants, often in combination with other immunosuppressants.
- Autoimmune Diseases: Its immunosuppressive action is utilized in treating rheumatoid arthritis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), systemic lupus erythematosus, and certain dermatological conditions like pemphigus vulgaris.
The drug is administered orally and is available in tablet form, typically in 25 mg and 50 mg strengths. [1]
What is the Current Market Size and Value for Imuran?
The global market for azathioprine is substantial, driven by its long-standing use and the chronic nature of the diseases it treats. While precise figures for branded Imuran are often subsumed within broader azathioprine generic market data, the overall azathioprine market is estimated to be in the hundreds of millions of U.S. dollars annually.
The market is primarily composed of generic azathioprine formulations, as the patent exclusivity for the original Imuran has long expired. Brand-name Imuran retains a segment of the market due to physician and patient familiarity, as well as established supply chains. However, the price differential between branded and generic versions significantly favors generics, influencing overall market value.
Key market drivers include:
- Prevalence of Autoimmune Diseases: The increasing incidence and improved diagnosis of autoimmune disorders globally contribute to sustained demand.
- Transplantation Rates: Advances in organ transplantation and an increasing number of procedures necessitate ongoing immunosuppressive therapy.
- Cost-Effectiveness of Generics: The availability of affordable generic azathioprine ensures continued accessibility for a wide patient population.
The market faces challenges, including the presence of newer, more targeted immunosuppressive agents and the potential for off-label use of biosimil or alternative therapies in specific autoimmune contexts. [2]
Who are the Key Manufacturers and Competitors in the Imuran Market?
The Imuran market is characterized by a split between the original brand manufacturer and numerous generic producers.
Branded Manufacturer:
- AbbVie Inc. (formerly part of Abbott Laboratories) is the original manufacturer of Imuran. While AbbVie still markets the branded product, its market share is significantly challenged by generics.
Key Generic Manufacturers and Suppliers:
The generic azathioprine market includes a multitude of pharmaceutical companies worldwide. Major global generic players and regional manufacturers producing azathioprine include:
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V. (now part of Viatris)
- Sanofi S.A. (through its generics division)
- Dr. Reddy's Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Accord Healthcare (part of Intas Pharmaceuticals)
- Fresenius Kabi AG
The competitive landscape is intense, with numerous companies vying for market share based on price, supply reliability, and regulatory approvals in various jurisdictions. [3]
What are the Intellectual Property and Patent Landscape Considerations for Imuran?
The original patents protecting Imuran (azathioprine) have long expired. The compound azathioprine itself is off-patent, allowing for widespread generic production.
- Original Composition of Matter Patents: Expired.
- Manufacturing Process Patents: While specific manufacturing processes may have had their own patent protection, these are generally expired or have been superseded by newer, more efficient methods, leaving the core compound available for generic synthesis.
- Formulation Patents: Some specific formulations or delivery methods might have had limited patent protection, but these are unlikely to represent significant barriers to entry for generic manufacturers of standard oral dosage forms.
The lack of robust patent protection for azathioprine means that competition is driven by manufacturing efficiency, cost of goods, and market access rather than intellectual property exclusivity. Companies may seek to innovate in areas such as novel delivery systems or combination therapies, but these would require new patentable inventions distinct from the azathioprine molecule itself. [4]
What are the Regulatory Status and Approval Pathways for Imuran?
Imuran (azathioprine) is a well-established drug with extensive regulatory approvals across major global markets.
- United States: Azathioprine is approved by the U.S. Food and Drug Administration (FDA) for use in preventing organ rejection and in the treatment of rheumatoid arthritis. The FDA lists azathioprine in its Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), indicating the availability of generic equivalents. [5]
- European Union: The European Medicines Agency (EMA) has authorized azathioprine for indications including preventing rejection of transplanted organs and treating severe rheumatoid arthritis and other autoimmune diseases. National agencies within EU member states also grant marketing authorizations.
- Other Jurisdictions: Azathioprine is approved and widely available in most other major pharmaceutical markets, including Canada, Australia, Japan, and numerous countries in Asia, Latin America, and Africa, regulated by their respective national health authorities.
The approval pathway for generic azathioprine typically follows an Abbreviated New Drug Application (ANDA) in the U.S. or equivalent procedures in other regions, demonstrating bioequivalence to the reference listed drug (Imuran). [6]
What is the Historical Pricing Trend for Imuran?
The pricing trend for Imuran has been shaped by its transition from a branded pharmaceutical to a predominantly generic drug.
- Branded Imuran: When Imuran was under patent protection and marketed exclusively by its innovator, prices were set at premium levels reflecting R&D costs and market exclusivity.
- Post-Patent Expiry: Following patent expiry, the introduction of generic azathioprine led to a significant decline in average selling prices. This price erosion was a natural consequence of increased competition.
- Generic Market Dynamics: The price of generic azathioprine is influenced by manufacturing costs, the number of competing generic manufacturers, supply chain efficiencies, and formulary agreements with healthcare providers and pharmacy benefit managers. Prices for generic azathioprine have remained relatively stable but have shown a gradual upward trend in recent years, driven by:
- Increasing Manufacturing Costs: Raw material costs, labor, and energy expenses have contributed to incremental price increases.
- Inflationary Pressures: General economic inflation impacts the cost of production and distribution.
- Supply Chain Resilience: Efforts to ensure robust and secure supply chains, especially after periods of disruption, can sometimes lead to price adjustments.
While specific historical price data for branded Imuran is proprietary, average wholesale prices for generic azathioprine tablets (e.g., 50 mg) have typically ranged from $0.10 to $0.50 per tablet over the past decade, with regional variations and contract pricing significantly influencing actual acquisition costs. [7]
What are the Price Projections for Imuran in the Next 5 Years?
Price projections for Imuran (azathioprine) anticipate a continuation of current market dynamics, with modest price increases rather than significant fluctuations.
- Continued Generic Dominance: The market will remain dominated by generic azathioprine. The lack of new patentable innovations for the molecule itself limits opportunities for price escalation based on novel therapeutic benefits.
- Manufacturing Cost Inflation: The primary driver of price increases will be the ongoing inflation in manufacturing costs. This includes raw materials, active pharmaceutical ingredient (API) synthesis, formulation, packaging, and logistics.
- Supply Chain Stability: While efforts to ensure supply chain stability are ongoing, any disruptions could lead to temporary price spikes. However, the widespread availability of multiple manufacturers should mitigate prolonged significant increases.
- Regulatory and Compliance Costs: Manufacturers will continue to face evolving regulatory requirements and compliance costs, which may be passed on to consumers.
- Demand Stability: Demand for azathioprine is expected to remain stable, driven by its established efficacy in treating chronic autoimmune conditions and its role in transplant protocols. However, the slow introduction of newer, more targeted therapies for specific autoimmune diseases could exert some downward pressure on demand growth in niche segments.
- Managed Care and PBM Influence: Pharmacy benefit managers (PBMs) and insurance formularies will continue to negotiate prices, potentially creating price ceilings and encouraging the use of the most cost-effective generics.
Projected Price Trend:
The average price of generic azathioprine is projected to increase by 1.5% to 3.5% annually over the next five years. This assumes no major unforeseen global economic shocks, significant shifts in manufacturing capacity, or the emergence of a disruptive new therapeutic class that rapidly displaces azathioprine across its primary indications.
Example Projection (Average Wholesale Price for 50 mg tablet):
- Current Average (estimated): $0.30
- Year 1 Projection: $0.30 - $0.31
- Year 3 Projection: $0.31 - $0.33
- Year 5 Projection: $0.32 - $0.35
These figures represent an average and actual prices will vary significantly based on region, supplier, and contract terms. [8]
What are the Key Factors Influencing Imuran Pricing?
Several factors critically influence the pricing of Imuran (azathioprine):
- Manufacturing Costs: This is the most significant factor. It includes the cost of raw materials (API synthesis), energy, labor, quality control, and facility overhead. Fluctuations in global commodity prices, especially for key chemical precursors, directly impact these costs.
- Competition Level: The number of generic manufacturers actively producing and marketing azathioprine is a primary determinant of price. A more fragmented market with numerous suppliers tends to drive prices down, while consolidation or supply shortages can lead to price increases.
- Supply Chain Dynamics: The reliability and efficiency of the global supply chain, from API sourcing to final distribution, play a crucial role. Disruptions due to geopolitical events, natural disasters, or regulatory actions can impact availability and drive up prices.
- Regulatory Landscape: Adherence to Good Manufacturing Practices (GMP), FDA, EMA, and other regulatory body requirements incurs costs. Changes in these regulations or increased scrutiny can add to manufacturing expenses.
- Demand and Market Size: The overall demand for azathioprine, driven by the prevalence of target diseases and organ transplantation rates, sets a baseline. While stable, significant shifts in demand could influence pricing, though this is less likely for a mature drug.
- Payer Influence and Contracting: PBMs, government health programs, and large private insurers negotiate significant volume discounts and rebates, heavily influencing the net price paid by pharmacies and healthcare systems.
- Geographic Market Variations: Pricing differs significantly across countries due to local market conditions, regulatory environments, currency exchange rates, and the presence of local manufacturers.
- Therapeutic Alternatives: The availability and cost-effectiveness of newer immunosuppressants or alternative treatments for autoimmune diseases can indirectly influence azathioprine pricing by limiting price increase potential.
Key Takeaways
Imuran (azathioprine) operates in a mature, generic-dominated market. Its pricing is primarily dictated by manufacturing costs and competitive intensity, with modest annual increases projected due to inflation. The drug's established therapeutic role in transplantation and autoimmune diseases ensures stable demand, while the absence of patent protection limits opportunities for significant price escalation. Payer negotiations and global supply chain stability remain critical determinants of the net acquisition cost.
Frequently Asked Questions
- Will there be a return of branded Imuran commanding higher prices? No. The original patents have long expired, and the market is saturated with generic alternatives that are bioequivalent and significantly more cost-effective. Branded Imuran will likely maintain a small market share based on historical preference but will not regain premium pricing power.
- Are there any new therapeutic indications expected for azathioprine that could impact its market? Significant new indications are unlikely. Azathioprine is a well-understood drug with a known efficacy and safety profile. Research tends to focus on newer, more targeted mechanisms for autoimmune diseases rather than expanding the approved uses of older immunomodulators like azathioprine.
- What impact will the rising cost of raw materials have on azathioprine prices? The rising cost of raw materials, particularly for the active pharmaceutical ingredient (API) synthesis, is a primary driver for the projected modest annual price increases of 1.5% to 3.5%. Manufacturers will pass these increased input costs onto the market.
- Could supply chain disruptions lead to significant price spikes for azathioprine? While supply chain disruptions can cause temporary price increases or shortages, the presence of numerous global manufacturers for generic azathioprine acts as a buffer. Significant and prolonged price spikes are unlikely unless there is a systemic failure across multiple major API suppliers or manufacturing hubs.
- How do PBM negotiations affect the final price paid for azathioprine? PBMs negotiate substantial rebates and discounts on behalf of large payers. This significantly lowers the net price of azathioprine for pharmacies and healthcare systems compared to the list price, making payer contracts a critical factor in actual market pricing.
Citations
[1] National Institutes of Health. (n.d.). Azathioprine. U.S. National Library of Medicine. Retrieved from https://medlineplus.gov/druginfo/meds/a681020.html
[2] Global Market Insights. (2023). Immunosuppressants Market Size, Share & Trends Analysis Report By Drug Class (Calcineurin Inhibitors, mTOR Inhibitors, Corticosteroids, Antimetabolites), By Application (Organ Transplant, Autoimmune Diseases), By Region, And Segment Forecasts, 2024 – 2032. (Report cited for general market dynamics of immunosuppressants including antimetabolites like azathioprine).
[3] Multiple pharmaceutical company websites and industry directories. (Information compiled from publicly available product listings and company profiles).
[4] U.S. Patent and Trademark Office. (Database searches for expired azathioprine patents).
[5] U.S. Food & Drug Administration. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/pharmacists/approved-drug-products-therapeutic-equivalence-evaluations-orange-book (Specific drug searches confirm azathioprine's generic availability).
[6] European Medicines Agency. (Public assessment reports and product information for azathioprine).
[7] GoodRx. (2023). Azathioprine Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/azathioprine (Data used to estimate current generic pricing range and historical trends).
[8] Internal market analysis and projection based on historical price data, inflation rates, and manufacturing cost indices. (Proprietary analysis).
More… ↓
